Pharmahungary Group Press release

Péter Ferdinandy, MD, PhD, MBA, the Founder & CEO of Pharmahungary Group, has been recognized as a ‘Highly Cited Researcher’ for the seventh time in 2024.

Summary: Budapest, Hungary, November 20, 2024. Péter Ferdinandy, MD, PhD, MBA, the Founder & CEO of Pharmahungary Group has been noticed as a ‘Highly Cited Researcher‘ for the 7th time in 2024. The ‘Highly Cited Researcher’ list is compiled by Clarivative includes less than 7,000 researchers worldwide in all disciplines who authored multiple Highly Cited Papers™. Of the world’s population of scientists and social scientists, Highly Cited Researchers are 1 in 1,000.

The ‘Highly Cited Researchers’ list for 2024 has been unveiled by Clarivate. Highly Cited Researchers have demonstrated significant and broad influence in their field(s) of research. This year less than 7,000 researchers have earned the recognition of ‘Highly Cited Researchers’ across all research fields. ‘Highly Cited Researchers’ authored multiple Highly Cited Papers™, ranking within the top 1% by citations for their respective field and year within the Web of Science™ database. However, citation activity is not the sole selection indicator. A preliminary list based on citation activity is then refined using qualitative analysis and expert judgement. Of the world’s population of scientists and social scientists, Highly Cited Researchers are 1 in 1,000.

Prof. Ferdinandy was acknowledged for the 7th time in 2024 as a ‘Highly Cited Researcher’ after 2014, 2017, 2020, 2021, 2022, and 2023. Considered as a key opinion leader in the pharmacology of cardioprotection, Prof. Ferdinandy also holds academic positions such as the Head of the Department of Pharmacology and Pharmacotherapy and the Vice-Rector for Science and Innovations of Semmelweis University, Budapest, Hungary. Moreover, he is the Editor-in-Chief of British Journal of Pharmacology since January 1st, 2023, the President of the Hungarian Society for Experimental and Clinical Pharmacology and Executive Committee member of the European Federation of Pharmacological Societies.

About Pharmahungary Group
Pharmahungary Group is an ISO 9001:2015 certified Hungarian SME developing innovative in-house R&D projects for valorization and providing preclinical and clinical R&D services since 2003. Pharmahungary Group also focusing on developing miRNA therapeutics, based on the 2024 Nobel prize winner technology. More information: www.pharmahungary.com.

Contact Pharmahungary Group
Andras Nogradi, Business Development Director
Graphisoft Park, Zahony str. 7., Budapest, H-1031, Hungary, European Union
e-mail: businessdevelopment@pharmahungary.com